The University of Shiga Prefecture · Faculty of Human Culture · 教授

Research keywordsCancer・Stromal・research・がん・マルチオミクス解析・代謝・化学・悪液質

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study .2027 · 記述言語： 英語 掲載種別： 研究論文（学術雑誌） OBJECTIVE: Due to the occurrence of severe adverse drug reactions to regorafenib, a drug used in cancer therapy, the identification of a predictive marker(s) is needed to increase the therapeutic applicability of this compound. We therefore investigated whether polymorphisms in the ABCG2 and SLCO1B genes are associated with adverse drug reactions to regorafenib. METHODS: For these analyses, 37 Japanese cancer patients were treated with regorafenib, genotyped for polymorphisms in ABCG2 and SLCO1B, and evaluated for drug-related adverse drug reactions. RESULTS: There was no association between the ABCG2 421C>A variant and adverse drug reactions to regorafenib. After treatment, the incidences of increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as well as increased total bilirubin (grade ≥ 2) were 8%, 4%, and 12%, and 42%, 25%, and 25% among SLCO1B1*1b carriers and non-carriers, respectively. There were no significant associations between elevated ALT and bilirubin and the SLCO1B1*1b allele. However, there were significantly lower incidences of increased AST (8% vs. 42%) and anemia (16% vs. 50%) in SLCO1B1*1b carriers than in non-carriers. CONCLUSIONS: The absence of SLCO1B1*1b allele appears to be associated with the development of adverse drug reactions to regorafenib; however, further studies involving larger test groups and other populations are needed to confirm these findings. . DOI： 10.5414/CP202788 PubMed researchmap
• TGF-β signaling promotes desmoid tumor formation via CSRP2 upregulation.2024 · 記述言語： 英語 掲載種別： 研究論文（学術雑誌） Desmoid tumors (DTs), also called desmoid-type fibromatoses, are locally aggressive tumors of mesenchymal origin. In the present study, we developed a novel mouse model of DTs by inducing a local mutation in the Ctnnb1 gene, encoding β-catenin in PDGFRA-positive stromal cells, by subcutaneous injection of 4-hydroxy-tamoxifen. Tumors in this model resembled histologically clinical samples from DT patients and showed strong phosphorylation of nuclear SMAD2. Knockout of SMAD4 in the model significantly suppressed tumor growth. Proteomic analysis revealed that SMAD4 knockout reduced the level of Cysteine-and-Glycine-Rich Protein 2 (CSRP2) in DTs, and treatment of DT-derived cells with a TGF-β receptor inhibitor reduced CSRP2 RNA levels. Knockdown of CSRP2 in DT cells significantly suppressed their proliferation. These results indicate that the TGF-β/CSRP2 axis is a potential therapeutic target for DTs downstream of TGF-β signaling. DOI： 10.1111/cas.16037 PubMed researchmap
• がんと全身性代謝変容 がん悪液質に伴う代謝臓器変容のマルチオミクス解析2024 · J-GLOBAL researchmap
• L-2hydroxyglutaric acid rewires amino acid metabolism in colorectal cancer via the mTOR-ATF4 axis2023 · 記述言語： 英語 掲載種別： 研究論文（学術雑誌） DOI： 10.1038/s41388-023-02632-7 Web of Science researchmap

• 代謝異常関連脂肪肝炎（MASH）の新規血液バイオマーカーの開発2026 · 担当区分： 研究代表者 researchmap
• 代謝異常関連脂肪肝炎(MASH)の血液診断バイオマーカーの開発2025 · 担当区分： 研究代表者 researchmap
• 肝臓脂質代謝検査方法の開発2025 · 担当区分： 研究代表者 researchmap
• 大腸がん幹細胞の未分化性維持機構の解明2025 · 配分額： 18850000円 （ 直接経費： 14500000円 、 間接経費： 4350000円 ） researchmap

• Official profile